Evidence map›Paper›PMID 35412354›Full record

ArticleAntimicrobial agents and chemotherapy2022

Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations.

Marie Desnos-Ollivier, Stéphane Bretagne, Olivier Lortholary, Françoise Dromer, French Mycoses Study Group N. Brieu CH Aix, T. Chouaki , C. Damiani , A. Totet CHU Amiens, J. P. Bouchara , D. Chabasse , M. Pihet CHU Angers, S. Bland CH Annecy, V. Blanc CH Antibes, S. Branger CH Avignon, A. P. Bellanger , L. Millon CHU Besançon, C. Plassart CH Beauvais, I. Poilane Hôpital Jean Verdier, Bondy, I. Accoceberry , L. Delhaes , B. Couprie , F. Gabriel CH Bordeaux, J. Dunand , A. L. Roux , V. Sivadon-Tardy Hôpital Ambroise Paré, Boulogne Billancourt, F. Laurent CH, Bourg en Bresse, S. Legal , E. Moalic , G. Nevez , D. Quinio CHU Brest, M. Cariou CH Bretagne Sud, J. Bonhomme , C. Duhamel CHU, Caen, B. Podac CH, Chalon sur Saône, S. Lechatch CH, Charleville-Mézières, C. Soler Hopital d’Instruction des armées, Clamart, M. Cambon , C. Nourrisson , P. Poirier , D. Pons CHU, Clermont Ferrand, O. Augereau , I. Grawey CH, Colmar, N. Fauchet CHIC, Créteil, A. Bonnin , F. Dalle CHU, Dijon, P. Cahen , P. Honderlick CMC, Foch, N. Desbois , C. Miossec CHU, Fort de France, J. L. Hermann Hôpital Raymond Poincaré, Garches, M. Cornet , R. Grillot , B. Lebeau , D. Maubon , H. Pelloux CHU, Grenoble, M. Nicolas CHU, Guadeloupe, C. Aznar , D. Blanchet , J. F. Carod , M. Demar CHU, Guyane, A. Angoulvant Hôpital Bicêtre, le Kremlin Bicêtre, C. Ciupek CH, Le Mans, A. Gigandon Hôpital Marie Lannelongue, Le Plessis Robinson, B. Bouteille CH Limoges, E. Frealle , D. Poulain , B. Sendid CHU Lille, D. Dupont , J. Menotti , F. Persat , M.-A. Piens , M. Wallon CHU, Lyon, C. Cassagne , S. Ranque CHU, Marseille, T. Benoit-Cattin , L. Collet CH Mayotte, A. Fiacre CH Meaux, N. Bourgeois , L. Lachaud , P. Rispail , Y. Sterkers CHU, Montpellier, M. Machouart CHU, Nancy, F. Gay-Andrieu , P. Lepape , F. Morio CHU, Nantes, O. Moquet CH, Nevers, S. Lefrançois Hôpital Américain, Neuilly, M. Sasso CHU, Nimes, F. Reibel GH, Nord-Essone, M. Gari-Toussaint , L. Hasseine CHU Nice, L. Bret , D. Poisson CHR Orléans, S. Brun Hôpital Avicenne, Paris, C. Bonnal , C. Chochillon , S. Houzé Hôpital Bichat, Paris, A. Paugam Hôpital Cochin, Paris, N. Ait-Ammar , F. Botterel , R. Chouk CHU Henri Mondor, Paris, M. E. Bougnoux , E. Sitterle Hôpital Necker, Paris, A. Fekkar , R. Piarroux Hôpital Pitié Salpêtrière, Paris, J. Guitard , C. Hennequin , J.-L. Poirot Hôpital St Antoine, Paris, M. Gits-Muselli , S. Hamane , C. Lacroix Hôpital Saint Louis, Paris, S. Bonacorsi , P. Mariani Hôpital Robert Debré, Paris, D. Moissenet Hôpital Trousseau, Paris, C. Kauffmann-Lacroix , A. Minoza , E. Perraud , M. H. Rodier CHU Poitiers, G. Colonna CH, Porto Vecchio, A. Huguenin , D. Toubas CHU Reims, S. Chevrier , J. P. Gangneux , F. Robert-Gangneux , C. Guigen CHU Rennes, O. Belmonte , G. Hoarau , M. C. Jaffar Bandjee , J. Jaubert , S. Picot , N. Traversier CHU Réunion, L. Favennec , G. Gargala CHU, Rouen, N. Godineau , C. Tournus CH, St Denis, C. Mahinc , H. Raberin CHU, St Etienne, V. Letscher Bru CHU, Strasbourg, S. Cassaing CHU, Toulouse, P. Patoz CH Tourcoing, E. Bailly , J. Chandenier , G. Desoubeaux CHU Tours, F. Moreau CH Troyes, P. Munier CH Valence, E. Mazars CH Valenciennes, O. Eloy CH Versailles, E. Chachaty Institut Gustave Roussy, Villejuif

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Antifungal Susceptibilities of Rare Yeast Isolates.Journal of fungi (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Activity of Rezafungin Against Echinocandin Non-wild typeOpen forum infectious diseases · 2025
    Article
  6. Antimicrobial agents and chemotherapy · 2024
    Article
  7. Epidemiology of Invasive Candidiasis.Clinical epidemiology · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Marie Desnos-OllivierInstitut Pasteurgrid.428999.7, Université de Paris, CNRS UMR2000, Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, Paris, France.ORCID 0000-0002-9137-0466
Stéphane BretagneInstitut Pasteurgrid.428999.7, Université de Paris, CNRS UMR2000, Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, Paris, France.
Olivier LortholaryInstitut Pasteurgrid.428999.7, Université de Paris, CNRS UMR2000, Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, Paris, France.
Françoise DromerInstitut Pasteurgrid.428999.7, Université de Paris, CNRS UMR2000, Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, Paris, France.ORCID 0000-0003-1671-1475
French Mycoses Study Group N. Brieu CH Aix, T. Chouaki , C. Damiani , A. Totet CHU Amiens, J. P. Bouchara , D. Chabasse , M. Pihet CHU Angers, S. Bland CH Annecy, V. Blanc CH Antibes, S. Branger CH Avignon, A. P. Bellanger , L. Millon CHU Besançon, C. Plassart CH Beauvais, I. Poilane Hôpital Jean Verdier, Bondy, I. Accoceberry , L. Delhaes , B. Couprie , F. Gabriel CH Bordeaux, J. Dunand , A. L. Roux , V. Sivadon-Tardy Hôpital Ambroise Paré, Boulogne Billancourt, F. Laurent CH, Bourg en Bresse, S. Legal , E. Moalic , G. Nevez , D. Quinio CHU Brest, M. Cariou CH Bretagne Sud, J. Bonhomme , C. Duhamel CHU, Caen, B. Podac CH, Chalon sur Saône, S. Lechatch CH, Charleville-Mézières, C. Soler Hopital d’Instruction des armées, Clamart, M. Cambon , C. Nourrisson , P. Poirier , D. Pons CHU, Clermont Ferrand, O. Augereau , I. Grawey CH, Colmar, N. Fauchet CHIC, Créteil, A. Bonnin , F. Dalle CHU, Dijon, P. Cahen , P. Honderlick CMC, Foch, N. Desbois , C. Miossec CHU, Fort de France, J. L. Hermann Hôpital Raymond Poincaré, Garches, M. Cornet , R. Grillot , B. Lebeau , D. Maubon , H. Pelloux CHU, Grenoble, M. Nicolas CHU, Guadeloupe, C. Aznar , D. Blanchet , J. F. Carod , M. Demar CHU, Guyane, A. Angoulvant Hôpital Bicêtre, le Kremlin Bicêtre, C. Ciupek CH, Le Mans, A. Gigandon Hôpital Marie Lannelongue, Le Plessis Robinson, B. Bouteille CH Limoges, E. Frealle , D. Poulain , B. Sendid CHU Lille, D. Dupont , J. Menotti , F. Persat , M.-A. Piens , M. Wallon CHU, Lyon, C. Cassagne , S. Ranque CHU, Marseille, T. Benoit-Cattin , L. Collet CH Mayotte, A. Fiacre CH Meaux, N. Bourgeois , L. Lachaud , P. Rispail , Y. Sterkers CHU, Montpellier, M. Machouart CHU, Nancy, F. Gay-Andrieu , P. Lepape , F. Morio CHU, Nantes, O. Moquet CH, Nevers, S. Lefrançois Hôpital Américain, Neuilly, M. Sasso CHU, Nimes, F. Reibel GH, Nord-Essone, M. Gari-Toussaint , L. Hasseine CHU Nice, L. Bret , D. Poisson CHR Orléans, S. Brun Hôpital Avicenne, Paris, C. Bonnal , C. Chochillon , S. Houzé Hôpital Bichat, Paris, A. Paugam Hôpital Cochin, Paris, N. Ait-Ammar , F. Botterel , R. Chouk CHU Henri Mondor, Paris, M. E. Bougnoux , E. Sitterle Hôpital Necker, Paris, A. Fekkar , R. Piarroux Hôpital Pitié Salpêtrière, Paris, J. Guitard , C. Hennequin , J.-L. Poirot Hôpital St Antoine, Paris, M. Gits-Muselli , S. Hamane , C. Lacroix Hôpital Saint Louis, Paris, S. Bonacorsi , P. Mariani Hôpital Robert Debré, Paris, D. Moissenet Hôpital Trousseau, Paris, C. Kauffmann-Lacroix , A. Minoza , E. Perraud , M. H. Rodier CHU Poitiers, G. Colonna CH, Porto Vecchio, A. Huguenin , D. Toubas CHU Reims, S. Chevrier , J. P. Gangneux , F. Robert-Gangneux , C. Guigen CHU Rennes, O. Belmonte , G. Hoarau , M. C. Jaffar Bandjee , J. Jaubert , S. Picot , N. Traversier CHU Réunion, L. Favennec , G. Gargala CHU, Rouen, N. Godineau , C. Tournus CH, St Denis, C. Mahinc , H. Raberin CHU, St Etienne, V. Letscher Bru CHU, Strasbourg, S. Cassaing CHU, Toulouse, P. Patoz CH Tourcoing, E. Bailly , J. Chandenier , G. Desoubeaux CHU Tours, F. Moreau CH Troyes, P. Munier CH Valence, E. Mazars CH Valenciennes, O. Eloy CH Versailles, E. Chachaty Institut Gustave Roussy, Villejuif
Centre National de la Recherche Scientifique · FRHôpital Necker-Enfants Malades · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since echinocandins are recommended as first line therapy for invasive candidiasis, detection of resistance, mainly due to alteration in FKS protein, is of main interest. EUCAST AFST recommends testing both MIC of anidulafungin and micafungin, and breakpoints (BPs) have been proposed to detect echinocandin-resistant isolates. We analyzed MIC distribution for all three available echinocandins of 2,787 clinical yeast isolates corresponding to 5 common and 16 rare yeast species, using the standardized EUCAST method for anidulafungin and modified for caspofungin and micafungin (AM3-MIC). In our database, 64 isolates of common pathogenic species were resistant to anidulafungin, according to the EUCAST BP, and/or to caspofungin, using our previously published threshold (AM3-MIC ≥ 0.5 mg/L). Among these 64 isolates, 50 exhibited 21 different FKS mutations. We analyzed the capacity of caspofungin AM3-MIC and anidulafungin MIC determination in detecting isolates with FKS mutation. They were always identified using caspofungin AM3-MIC and the local threshold while some isolates were misclassified using anidulafungin MIC and EUCAST threshold. However, both methods misclassified four wild-type C. glabrata as resistant. Based on a large data set from a single center, the use of AM3-MIC testing for caspofungin looks promising in identifying non-wild-type C. albicans, C. tropicalis and P. kudiravzevii isolates, but additional multicenter comparison is mandatory to conclude on the possible superiority of AM3-MIC testing compared to the EUCAST method.

Indexed as

Candidiasis, InvasiveEchinocandinsAnidulafunginAntifungal AgentsCaspofunginDrug Resistance, FungalHumansLipopeptidesMicafunginMicrobial Sensitivity TestsMutationAnidulafunginAntifungal AgentsCaspofunginEchinocandinsLipopeptidesMicafunginanidulafunginantifungal resistancecaspofungincommon yeastFKS mutationmicafunginMIC distributionrare yeastyeasts

Identifiers

PMID35412354
PMCPMC9116480
OpenAlexW4223435645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.